Form 4: ImmuCell CEO Granted Stock Options
Insider Transaction Report
ImmuCell's President and CEO, Paul Francis Olivier te Boekhorst, was granted 74,277 stock options with an exercise price of $6.10, vesting over three years.
Summary
- Paul Francis Olivier te Boekhorst, President and CEO of ImmuCell Corp, was granted 74,277 stock options.
- The options have an exercise price of $6.10 per share.
- The grant date is November 7, 2025, and the options expire on November 7, 2035.
- The options vest in three equal annual installments of 24,759 options on the first, second, and third anniversaries of the grant date.
- This grant is in connection with his commencement of employment as President and CEO.
- Following this transaction, Mr. te Boekhorst beneficially owns 150,260 derivative securities.
Sentiment
Score: 7
Explanation: The grant of stock options to the President and CEO is a standard practice to align executive incentives with shareholder value, indicating commitment and long-term focus.
Positives
- The grant of stock options to the President and CEO aligns management's interests with shareholders, incentivizing long-term performance.
- The options are tied to the commencement of employment for the President and CEO, indicating a commitment to the company.
Future Outlook
NA
Industry Context
NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| President and CEO | Not specified in filing | Paul Francis Olivier te Boekhorst | 11/07/2025 | Commencement of employment |
Stakeholder Impact
- Shareholders: Potential positive impact due to increased alignment of the CEO's interests with long-term company performance.
- Management: The CEO receives a significant equity incentive as part of their compensation package.
Next Steps
- Vesting of 24,759 options on the first anniversary of the grant date (November 7, 2026).
- Vesting of 24,759 options on the second anniversary of the grant date (November 7, 2027).
- Vesting of 24,759 options on the third anniversary of the grant date (November 7, 2028).
Key Dates
| Date | Description |
|---|---|
| 11/07/2025 | Transaction Date for stock option grant and Date Exercisable. |
| 11/11/2025 | Signature Date of the filing. |
| 11/07/2035 | Expiration Date of the stock options. |
Recommendation
holdThe filing details a standard executive compensation event, specifically an option grant to the new President and CEO. While this aligns management's long-term interests with shareholders, it does not provide new information on the company's operational or financial performance to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate based solely on this filing.
Keywords
ImmuCell, ICCC, stock options, insider transaction, CEO compensation, executive compensation, Form 4, Paul Francis Olivier te Boekhorst
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.